在类风湿性关节炎中，爱泼斯坦-巴尔病毒、淋巴瘤和肿瘤坏死因子拮抗作用之间有什么联系？

What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis?

作者信息

Balandraud Nathalie, Roudier Jean, Roudier Chantal

机构信息

INSERM UMR 639, Immunogenetics of RA, Faculté de médecine, Marseille, France.

出版信息

Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):31-3. doi: 10.1016/j.semarthrit.2005.01.008.

DOI:10.1016/j.semarthrit.2005.01.008

PMID:15852253

Abstract

EPSTEIN-BARR VIRUS (EBV) AND RHEUMATOID ARTHRITIS (RA): Patients with (RA) have slightly impaired EBV specific immunity. EBV AND LYMPHOMA: EBV contributes to the development of lymphoma, especially in immunosuppressed patients. LYMPHOMA IN RA: The incidence of lymphoma is increased (2-fold) in patients with active RA. TUMOR NECROSIS FACTOR (TNF) ANTAGONISM, LYMPHOMA, AND RA: The risk to develop lymphoma in patients with RA under TNF inhibitors is slightly higher than that of patients with active RA who do not receive TNF inhibitors. As already demonstrated in the case of posttransplantation lymphoma, EBV load monitoring in patients with RA under TNF inhibitors might allow predicting and preventing the emergence of lymphoma.

摘要

爱泼斯坦-巴尔病毒（EBV）与类风湿关节炎（RA）：类风湿关节炎患者的EBV特异性免疫略有受损。EBV与淋巴瘤：EBV促使淋巴瘤的发生，尤其在免疫抑制患者中。类风湿关节炎中的淋巴瘤：活动期类风湿关节炎患者的淋巴瘤发病率增加（两倍）。肿瘤坏死因子（TNF）拮抗剂、淋巴瘤与类风湿关节炎：类风湿关节炎患者使用TNF抑制剂时发生淋巴瘤的风险略高于未接受TNF抑制剂的活动期类风湿关节炎患者。正如移植后淋巴瘤的情况所示，对使用TNF抑制剂的类风湿关节炎患者进行EBV载量监测可能有助于预测和预防淋巴瘤的出现。